Emcure Pharma IPO GMP

Emcure Pharma IPO: Subscription Frenzy and Record GMP Prices

Emcure Pharma IPO sees huge demand with shares selling at a premium of ₹333 in the grey market. Check out the subscription status and latest updates!

The Emcure Pharmaceuticals IPO has taken the market by storm with shares trading at a premium of ₹333 in the grey market on Day 2. Investors are showing tremendous interest as the IPO has been subscribed 3.36 times so far, indicating a strong market response. The Pune-based company is offering shares in the price band of Rs 960-1008, attracting investors with a potential listing gain. Emcure Pharma IPO received 1.86x subscription on Day 2, fueling excitement among potential investors.

The grey market is buzzing with anticipation, with unlisted shares of Emcure Pharma trading at a significant premium of Rs 330, signaling a potential 32.74% listing gain. This surge in grey market prices reflects the high demand for Emcure Pharma shares. The IPO subscription status on Day 1 reached 75%, driven by enthusiastic participation from employees and non-institutional investors.

Emcure Pharma's IPO GMP today is creating a frenzy in the market, with investors eager to capitalize on the opportunity. Bain Capital-backed Emcure Pharmaceuticals saw full subscription by 1.32 times on the first day of the share-sale, showcasing investor confidence in the company. Arun Mantri from Mantri Finmart has given a strong 'subscribe' recommendation for the Emcure Pharma IPO, emphasizing the potential for growth and gains.

The Emcure Pharmaceuticals IPO has witnessed overwhelming demand, with subscription levels soaring to 4.98 times, reflecting investor confidence in the company. The IPO, supported by Bain Capital, has raised ₹583 crore from anchor investors, setting the stage for a successful debut in the market.